Standalone Financial Results (Q1 FY27 ended June 30, 2026)
Revenue from operations: ₹26,561 million vs ₹21,679 million in Q1 FY26 (22.5% YoY growth)
Total income: ₹27,032 million vs ₹22,004 million in Q1 FY26
Profit before tax: ₹5,007 million vs ₹3,966 million in Q1 FY26
Profit after tax: ₹3,852 million vs ₹3,069 million in Q1 FY26
Basic EPS: ₹26.79 vs ₹21.35 in Q1 FY26
EBITDA: ₹6,562 million vs ₹5,461 million in Q1 FY26
Exceptional item: ₹114 million charge in FY26 due to Labour Codes implementation impact
Consolidated Financial Results (Q1 FY27 ended June 30, 2026)
Revenue from operations: ₹70,435 million vs ₹58,421 million in Q1 FY26 (20.6% YoY growth)
Total income: ₹70,923 million vs ₹58,823 million in Q1 FY26
Profit before tax: ₹7,988 million vs ₹5,827 million in Q1 FY26
Profit after tax: ₹6,104 million vs ₹4,410 million in Q1 FY26
PAT attributable to owners: ₹5,807 million vs ₹4,328 million in Q1 FY26
Basic EPS: ₹40.39 vs ₹30.10 in Q1 FY26
Exceptional item: ₹192 million charge in FY26 due to Labour Codes implementation impact
Segment-wise Performance (Consolidated Q1 FY27)
Healthcare services revenue: ₹36,195 million (22% YoY growth)
Retail health and diagnostics revenue: ₹4,995 million
Digital health and pharmacy distribution revenue: ₹29,770 million (20% YoY growth)
Healthcare services EBITDA: ₹6,859 million
Retail health and diagnostics EBITDA: ₹227 million
Digital health and pharmacy distribution EBITDA: ₹1,523 million
Statutory Auditor Appointment
Board approved appointment of M/s Price Waterhouse Chartered Accountants LLP (ICAI Firm Registration No.: 012754N/N500016) as statutory auditors for five-year term commencing from conclusion of 46th AGM (to be held in 2027) until conclusion of 51st AGM (to be held in 2032)
Subject to shareholder approval and statutory compliance requirements
Current auditor M/s Deloitte Haskins & Sells LLP (ICAI Firm Registration No. 117366W/W-100018) will continue until conclusion of 46th AGM
Price Waterhouse has 17 branch offices in India and over 120 assurance partners as of April 1, 2026
Subsidiary Restructuring
Apollo Healthco Limited (AHL), a material subsidiary, will transfer its FMCG wholesale distribution business (Transferred Undertaking) to Apollo Consumer Products Limited (ACPL), its wholly-owned subsidiary
Transaction to be executed on slump sale basis as going concern, subject to AHL shareholder approval
Transferred Undertaking FY26 turnover: ₹36,097 million (14.31% of consolidated turnover)
Transferred Undertaking FY26 net worth: ₹5,959 million (5.97% of consolidated net worth)
Consideration to be lump sum cash equivalent to fair market value determined under Income Tax Rules
Expected completion date: October 1, 2026, or mutually agreed date
Rationale: Segregate business for enhanced group efficiency
ESOP Grants
Granted 36,848 stock options and 9,949 RSUs aggregating to 46,798 equity shares of ₹5 each under Apollo ESOP Plan 2024
Exercise price for options: ₹5,874 per share (20% discount to weighted average market price April 2025-March 2026)
Vesting schedule: 40% after 2 years, 30% after 3 years, 30% after 4 years from grant date
Vested options exercisable within 3 years from respective vesting dates
Scheme compliant with SEBI (Share Based Employee Benefits) Regulations, 2021
Corporate Developments
Composite Scheme of Arrangement approved June 30, 2025, for demerger of omni-channel pharmacy and digital health businesses into Apollo Healthtech Limited
NCLT petition filed after receiving requisite approvals from secured creditors, unsecured creditors, and equity shareholders on June 24, 2026
Business Framework Agreement executed between AHEL and AHL on June 30, 2025, for independent business pursuit and collaboration
Board approved merger of Apollo Hospitals North Limited (wholly-owned subsidiary) with company on May 20, 2026
AHLL to combine with Kids Clinic India Limited (Cloudnine) creating maternity and fertility care platform
AHLL to divest stake in Apollo Specialty Hospitals and Apollo Fertility Centre to Kids Clinic at enterprise value of approximately ₹15,500 million
Regulatory Impact
Labour Codes implementation notified November 21, 2025, resulted in exceptional charge of ₹114 million (standalone) and ₹192 million (consolidated) for FY26 due to increased gratuity and leave liabilities
Imperial Hospitals and Research Centre Limited (subsidiary) facing land allotment dispute with Karnataka Revenue Department
Revenue Department cancellation order dated February 13, 2026, stayed by Karnataka High Court on April 10, 2026
Company believes it has adequate grounds to demonstrate compliance
Board Meeting Details
Meeting held on August 12, 2026
Commenced at 4:35 PM, concluded at 7:00 PM
Financial results approved after review by Audit Committee on August 11, 2026
